• Теги
    • избранные теги
    • Компании170
      • Показать ещё
      Разное38
      • Показать ещё
      Страны / Регионы60
      • Показать ещё
      Международные организации4
      Показатели4
      Люди3
      Сферы1
      Издания2
Astellas Pharma
Выбор редакции
30 января, 15:35

Ironwood/Astellas Report Positive Phase III Data on Linzess

Ironwood (IRWD) and partner Astellas reported positive top-line data from a phase III study on Linzess in adults with chronic constipation.

27 января, 17:19

Ironwood-Allergan Linzess Gets FDA Approval in Lower Dose

Ironwood Pharmaceuticals, Inc. (IRWD) and partner Allergan plc (AGN) announced that the FDA has approved a lower dose strength of Linzess (linaclotide) ??? 72 mcg ??? for the treatment of adult patients with chronic idiopathic constipation (CIC).

24 января, 17:55

Theravance's Infection Drug Vibativ Positive in TOUR Study

Theravance Biopharma, Inc. (TBPH) recently released positive interim data from the ongoing TOURstudy evaluating how Vibativ (telavancin) is used to treat patients with bacteremia or infective endocarditis (IE).

20 декабря 2016, 17:44

Amgen Files for Approval of Osteoporosis Drug in Japan

Amgen Inc. (AMGN) and partner UCB SA (UCBJF) announced that they have submitted an application seeking marketing approval for its investigational monoclonal antibody romosozumab to Japan's Pharmaceuticals and Medical Devices Agency (PMDA).

Выбор редакции
29 ноября 2016, 14:31

Гендиректор "Драгон Капитал" Фиала в третий раз стал президентом Европейской бизнес ассоциации

Обновленное правление Европейской бизнес ассоциации (ЕБА) 28 ноября избрало президентом генерального директора и основателя инвестиционной компании "Драгон Капитал" Томаша Фиалу, который после годичной паузы в третий раз возглавил ассоциацию.

25 ноября 2016, 18:02

Intro Guide to the Fidelity Pacific Basin (FPBFX) Fund

Fidelity Pacific Basin Fund (FPBFX) a Zacks Rank #2 (Buy) was incepted in October 1986 and is managed by Fidelity Group

24 ноября 2016, 07:33

Ситуация на фондовых площадках Азиатско-Тихоокеанского региона:

Основные фондовые индексы Азиатско-Тихоокеанского региона торгуются разнонаправленно. Большинство азиатских фондовых рынков упали в четверг, как оптимистичные экономические данные укрепили перспективу для более высоких процентных ставок в США. Акции на фондовых рынках Австралии торговались в зеленой зоне. Котировки в Китае находились около нулевой черты. Цены на акции на крупнейшей в Азии Токийской фондовой бирже растут, достигнув одиннадцатимесячного максимума на фоне подъема в Нью-Йорке. продолжающееся укрепление курса доллара к иене также очень положительно сказывается на настроении инвесторов, поскольку повышает прибыль крупных местных корпораций, ориентирующихся на внешние рынки. Напомним, вчера японские рынки были закрыты и сегодня перспективы выручки экспортеров улучшились. Автопроизводители были востребованы. Акции Toyota Motor Corp подорожали на 3,3%, а Honda Motor Co - на 3,0%. С другой сторона производители лекарств понесли убытки. Рыночная стоимость Takeda Pharmaceutical снизилась на 0,9%, Astellas Pharma потеряли 0,5 стоимость акций, а ценные бумаги Eisai Co рухнули на 5%. Nikkei 225 18,338.85 +175.91 +0.97% Shanghai Composite 3,247.24 +6.10 +0.19% S&P/ASX 200 5,479.70 -4.66 -0.08%Источник: FxTeam

07 ноября 2016, 16:39

Pharma Stock Roundup: Pfizer, Allergan Q3 Results Fall Short, Insulin Drugmakers under Pricing Pressure

Both Pfizer (PFE) and Allergan fell short of expectations while reporting Q3 earnings results. Meanwhile, the industry remains under drug pricing pressure.

Выбор редакции
21 сентября 2016, 21:35

ФАС выявила препараты, цены на которые в России выше минимальных цен в других странах

Федеральная антимонопольная служба (ФАС) установила случаи завышения цен на ряд лекарственных препаратов из списка программы госзакупки лекарств «7 нозологий». Как отмечается в сообщении ведомства, цены на ряд лекарств в России оказались выше минимальных цен в некоторых других странах мира. В частности, предельные цены по 48 позициям лекарственных препаратов, зарегистрированным в России, оказались в среднем выше на 39%, чем в других странах мира. В этот список попали препараты компании Astellas Pharma, Johnson & Johnson, Novartis, Teva, Roche, KRKA, Celgene.

21 сентября 2016, 21:35

ФАС выявила препараты, цены на которые в России выше минимальных цен в других странах

Федеральная антимонопольная служба (ФАС) установила случаи завышения цен на ряд лекарственных препаратов из списка программы госзакупки лекарств «7 нозологий». Как отмечается в сообщении ведомства, цены на ряд лекарств в России оказались выше минимальных цен в некоторых других странах мира. В частности, предельные цены по 48 позициям лекарственных препаратов, зарегистрированным в России, оказались в среднем выше на 39%, чем в других странах мира. В этот список попали препараты компании Astellas Pharma, Johnson & Johnson, Novartis, Teva, Roche, KRKA, Celgene.

Выбор редакции
20 сентября 2016, 23:16

Vical Slumps, Cytomegalovirus Vaccine Fails in Phase II Study

Vical (VICL) and Astellas reported disappointing top-line phase II data on cytomegalovirus vaccine candidate, ASP0113, in kidney transplant patients.

05 сентября 2016, 15:38

Drug Stocks Remain in Focus as Pricing Debate Continues

Mylan (MYL) finds itself in troubled waters with lawmakers now questioning Medicaid rebates for EpiPen.

23 августа 2016, 11:50

Pfizer to Buy Medivation for $14B, Boost Cancer Franchise (revised)

Pfizer (PFE) is buying cancer-focused Medivation for $14 billion with the deal slated to close in the third or fourth quarter.

Выбор редакции
23 августа 2016, 00:06

Pfizer (PFE) Bought Medivation (MDVN), but is it a Good Deal?

Pfizer is paying $14 billion for Medivation Inc, but is it worth it?

22 августа 2016, 19:10

Pfizer paying US$14b for Medivation

PFIZER will pay about US$14 billion in cash for cancer drug company Medivation, a deal that will add the pricey late-stage prostate cancer treatment Xtandi to its oncology portfolio. The New York drugmaker

22 августа 2016, 15:31

Pfizer to Buy Medivation for $14B, Boost Cancer Franchise

Pfizer (PFE) is buying cancer-focused Medivation for $14 billion with the deal slated to close in the third or fourth quarter.

22 августа 2016, 14:27

Another Big Pharma Merger

Pfizer says it’s buying Medivation for $14 billion.

22 августа 2016, 13:58

Pfizer Acquires Prostate Drug Maker Medivation For $81.50, 21% Premium To Closing

As was leaked over the weekend, first by the FT, moments ago Pfizer, still stinging from its foiled mega-acquisition of Allergan earlier in the year, announced it would acquire prostate-cancer drug maker Medivation for $81.50, a 21% premium to the Friday closing price, in a $14 billion deal. Before the Pfizer deal was announced, there had long been speculation that MDVN would be acquired as Medivation was one of the few independent biotech companies left with a cancer treatment that is already approved and selling well. CEO David Hung says he decided to found the company after watching a 28-year-old breast-cancer patient die during his oncology fellowship. The firm's blockbuster drug, Xtandi has held its own against a rival prostate-cancer treatment from Johnson & Johnson called Zytiga. Xtandi could be one of the top-selling cancer drugs by 2020, according to EvaluatePharma. The move will add "one of the crown jewels of the multibillion-dollar market for cancer drugs to Pfizer’s portfolio." The impetus behind the transaction is that Medivation’s drug, Xtandi, already generates about $2 billion in yearly sales and has the potential to more than double, according to analysts. Pfizer has been seeking to expand its lineup of such oncology treatments. Xtandi would give the New York drug company a beachhead in prostate cancer complementing its breast-cancer treatment Ibrance, which is on track to be a blockbuster. Further, as the WSJ adds, Medivation’s drugs in development could also complement Pfizer’s efforts to develop combinations of cancer agents with so-called immunotherapies, which deploy the immune system in the fight against cancer. The acquisition would also further Pfizer CEO Ian Read’s efforts to bolster what he refers to as the innovative side of the company’s business. Read has said Pfizer would decide by year’s end whether to split into two, with one company selling fast-growing brand-name drugs like Ibrance and another selling drugs that have lost patent protection. The full press release below. Pfizer to Acquire Medivation Propels Pfizer into a leading position in oncology Medivation agrees to transaction valued at $81.50 per Medivation share in cash, for a total enterprise value of approximately $14 billion Expected to be immediately accretive to Pfizer's Adjusted Diluted EPS upon closing, approximately $0.05 accretive in first full year after close with additional accretion and growth anticipated thereafter Pfizer Inc. (PFE) and Medivation, Inc. (MDVN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Medivation, a biopharmaceutical company focused on developing and commercializing small molecules for oncology, for $81.50 a share in cash for a total enterprise value of approximately $14 billion. The Boards of Directors of both companies have unanimously approved the merger, which is expected to be immediately accretive to Pfizer's Adjusted Diluted EPS upon closing, approximately $0.05 accretive in the first full year after close with additional accretion and growth anticipated thereafter. Pfizer does not expect the transaction to impact its current 2016 financial guidance. "The proposed acquisition of Medivation is expected to immediately accelerate revenue growth and drive overall earnings growth potential for Pfizer," said Ian Read, Chairman and Chief Executive Officer, Pfizer. "The addition of Medivation will strengthen Pfizer's Innovative Health business and accelerate its pathway to a leadership position in oncology, one of our key focus areas, which we believe will drive greater growth and scale of that business over the long-term. This transaction is another example of how we are effectively deploying our capital to generate attractive returns and create shareholder value." Medivation's portfolio includes XTANDI® (enzalutamide), an androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway within the tumor cell. XTANDI is the leading novel hormone therapy in the United States today and generated approximately $2.2 billion in worldwide net sales over the past four quarters, as recorded by Astellas Pharma Inc., with whom Medivation entered an agreement in 2009 to develop XTANDI globally and commercialize jointly in the U.S. Since its approval for advanced metastatic prostate cancer by the U.S. Food and Drug Administration in 2012, XTANDI has treated 64,000 men to date in the U.S. alone. Medivation and Astellas have built a robust development program for XTANDI, including two Phase 3 studies in non-metastatic prostate cancer and another Phase 3 study in hormone-sensitive prostate cancer. It is also being further developed in Phase 2 studies for the potential treatment of advanced breast cancer and hepatocellular carcinoma. In addition, Medivation has a promising, wholly-owned, late-stage oncology pipeline, which includes two development-stage oncology assets, talazoparib and pidilizumab. Talazoparib, currently in a Phase 3 study for the treatment of BRCA-mutated breast cancer, has the potential to be a highly potent PARP inhibitor and could be efficacious across several additional tumors. Pidilizumab is an immune-oncology (IO) asset being developed for diffuse large B-cell lymphoma and other hematologic malignancies and has the potential to be combined with IO therapies in Pfizer's portfolio. "We believe the combination with Pfizer is the right next step in our growth trajectory and is a testament to the passion and dedication by which the Medivation team has delivered on our mission to profoundly transform patients' lives through medically innovative therapies," said David Hung, M.D., founder, president and CEO of Medivation. "This compelling transaction will deliver significant and immediate value to our stockholders and provides new opportunities for our employees as part of a larger company. We believe that Pfizer is the ideal partner to extend the reach of our blockbuster XTANDI franchise and take our promising, late-stage assets -- talazoparib and pidiluzimab -- to their next stages of development so that they can be made available to patients as quickly as possible." "The proposed acquisition of Medivation will build upon Pfizer's success with our IBRANCE® (palbociclib) launch in HR+/HER2- metastatic breast cancer and with our strong immuno-oncology portfolio, and will transform Pfizer into a leading oncology company," said Albert Bourla, Group President, Pfizer Innovative Health. "IBRANCE and XTANDI are anchor brands in breast and prostate cancer respectively, giving Pfizer leadership in two hormone-driven cancers. Similar to IBRANCE in the breast cancer setting, XTANDI is being explored for its potential to move from metastatic prostate cancer to treat earlier stages of non-metastatic prostate cancer. In addition, Medivation's portfolio within prostate cancer and across diverse tumors will complement Pfizer's broad IO portfolio. Finally, Medivation adds commercial scale to better compete with other top tier oncology companies in advance of the potential emergence of Pfizer's IO pipeline expected in the next few years. Together, we believe Pfizer and Medivation can bring the full force of our combined research and resources to combat two of the most common cancers, as well as speed cures and make accessible breakthrough medicines to patients, redefining life with cancer." Cancer remains the second leading cause of death in the U.S. and a "Top 10" killer worldwide. According to the American Cancer Society, breast cancer and prostate cancer are among the top three cancers by annual incidence in the U.S. There are several parallels between breast and prostate cancer, including the incidence of prostate cancer in the U.S., which is similar to that of breast cancer with approximately 280,000 cases per year. Pfizer expects to finance the transaction with existing cash. Under the terms of the merger agreement, a subsidiary of Pfizer will commence a cash tender offer to purchase all of the outstanding shares of Medivation common stock for $81.50 per share, net to the seller in cash, without interest, subject to any required withholding of taxes. The closing of the tender offer is subject to customary closing conditions, including U.S. antitrust clearance and the tender of a majority of the outstanding shares of Medivation common stock. The merger agreement contemplates that Pfizer will acquire any shares of Medivation that are not tendered into the offer through a second-step merger, which will be completed promptly following the closing of the tender offer. Pfizer expects to complete the acquisition in the Third- or Fourth-Quarter 2016. Pfizer's financial advisors for the transaction were Guggenheim Securities and Centerview Partners, with Ropes & Gray LLP acting as its legal advisor. J.P. Morgan Securities and Evercore served as Medivation's financial advisors, while Cooley LLP and Wachtell, Lipton, Rosen & Katz served as its legal advisors.